- Home
- RVMD vs EQR Comparison
RVMD vs EQR Comparison
Compare RVMD & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | EQR |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 24.3B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | RVMD | EQR |
|---|---|---|
| Price | $140.79 | $65.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 13 |
| Target Price | ★ $140.84 | $69.63 |
| AVG Volume (30 Days) | ★ 3.7M | 2.3M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.29% |
| EPS Growth | N/A | ★ 8.09 |
| EPS | N/A | ★ 2.94 |
| Revenue | N/A | ★ $2,701,075,000.00 |
| Revenue This Year | N/A | $4.07 |
| Revenue Next Year | $533.02 | $3.14 |
| P/E Ratio | ★ N/A | $22.27 |
| Revenue Growth | N/A | ★ 4.76 |
| 52 Week Low | $34.00 | $57.57 |
| 52 Week High | $155.70 | $72.40 |
Technical Indicators
Market Signals| Indicator | RVMD | EQR |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 68.87 |
| Support Level | $93.39 | $61.10 |
| Resistance Level | $155.70 | $66.36 |
| Average True Range (ATR) | 7.53 | 1.30 |
| MACD | -0.07 | 0.44 |
| Stochastic Oscillator | 75.43 | 84.40 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.